Abstract:Therapeutic targeting of tumor vulnerabilities is emerging as a key area of research. This review is focused on exploiting the vulnerabilities of tumor cells and the immune cells in the tumor immune microenvironment (TIME), including tumor hypoxia, tumor acidity, the bidirectional proton-coupled monocarboxylate transporters (MCTs) of lactate, mitochondrial oxidative phosphorylation (OXPHOS), and redox enzymes in the tricarboxylic acid cycle. Cancer cells use glucose for energy even under normoxic conditions. Although cancer cells predominantly rely on glycolysis, many have fully functional mitochondria, suggesting that mitochondria are a vulnerable target organelle in cancer cells. Thus, one key distinction between cancer and normal cell metabolism is metabolic reprogramming. Mitochondria-targeted small molecule inhibitors of OXPHOS inhibit tumor proliferation and growth. Another hallmark of cancer is extracellular acidification due lactate accumulation. Emerging results show that lactate acts as a fuel for mitochondrial metabolism and supports tumor proliferation and growth. Metabolic reprogramming occurs in glycolysis-deficient tumor phenotypes and in kinase-targeted, drug-resistant cancers overexpressing OXPHOS genes. Glycolytic cancer cells located away from the vasculature overexpress MCT4 transporter to prevent overacidification by exporting lactate, and the oxidative cancer cells located near the vasculature express MCT1 transporter to provide energy through incorporation of lactate into the tricarboxylic acid cycle. MCTs are, therefore, a vulnerable target in cancer metabolism. MCT inhibitors exert synthetic lethality in combination with metformin, a weak inhibitor of OXPHOS, in cancer cells. Simultaneously targeting multiple vulnerabilities within mitochondria shows synergistic antiproliferative and antitumor effects. Developing tumor-selective, small molecule inhibitors of OXPHOS with a high therapeutic index is critical to fully exploiting the mitochondrial vulnerabilities. We and others developed small-molecule inhibitors containing triphenylphosphonium cation that potently inhibit OXPHOS in tumor cells and tissues. Factors affecting tumor cell vulnerabilities also impact immune cells in the TIME. Glycolytic tumor cells supply lactate to the tumor-suppressing regulatory T cells overexpressing MCTs. Therapeutic opportunities for targeting vulnerabilities in tumor cells and the TIME, as well as the implications on cancer health disparities and cancer treatment, are addressed.

Tumour immunogenicity goes with the (mitochondrial electron) flow

Manipulating mitochondrial electron flow enhances tumor immunogenicity

Research Progress on Mitochondria Regulating Tumor Immunity.

Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy

Mitochondrial Immune Regulation and Anti-Tumor Immunotherapy Strategies Targeting Mitochondria

Immunometabolic characteristics of Dendritic Cells and its significant modulation by mitochondria-associated signaling in the tumor microenvironment influence cancer progression

Mitochondrial ubiquinol oxidation is necessary for tumour growth

Metabolic control of tumour progression and antitumour immunity.

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

Inhibition Of Mitochondrial Complex Ii Induces Mitophagy And Attenuates Cell Proliferation

Metabolic Control of Tumour Progression and Antitumour Immunity

Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance

Tumor microenvironment induced switch to mitochondrial metabolism promotes suppressive functions in immune cells

Mitochondrial Elongation-Mediated Glucose Metabolism Reprogramming is Essential for Tumour Cell Survival During Energy Stress.

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy

Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth

Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology

Inhibition of Mitochondrial Fission Reverses the Immunoescape of Solid Tumors via IRE1α-XBP-1s-TPP2 axis

Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities